Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Jun 14;11(9):880-5.
doi: 10.7150/ijms.9165. eCollection 2014.

Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial

YanGang Wang  1 , Luan Wang  1 , EnZe Li  2 , Yang Li  1 , ZhongChao Wang  1 , XiaoFang Sun  1 , XiaoLong Yu  1 , Lin Ma  2 , YunLong Wang  3 , YouXin Wang  4
Affiliations
Randomized Controlled Trial

Chuanhu anti-gout mixture versus colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial

YanGang Wang et al. Int J Med Sci. .

Abstract

Background: The Chuanhu anti-gout mixture has been used for many years in the treatment of gout in Chinese Traditional Medicine, and current methods for treatments for acute gouty arthritis have been either less effective or have had serious side effects.

Methods: In this 12-week, double-blind, double-dummy, non-inferiority study, outpatient individuals with newly diagnosed acute gouty arthritis were randomly assigned to receive Chuanhu anti-gout mixture or colchicine. Both the study investigators and the participants were masked to the treatment assignments. The primary outcome was the recurrence rate of acute gouty arthritis, and the secondary outcomes were changes in white blood cells (WHC) and C-reactive protein (CRP). This trial is registered at ISRCTN.org as trial ISRCTN65219941.

Results: A total of 176 patients were randomly assigned to receive either the Chuanhu anti-gout mixture or Colchicine. The overall recurrence rates in the Chuanhu anti-gout mixture group (CH group) and the Colchicine group (Col group) were 12.50% vs 14.77% (difference -2.22%, 95% confidence interval (95% CI): -10.78%~6.23%), meeting the predefined non-inferiority criterion of 15%, as did the data for WHC and CRP. The incidence of adverse events (mainly diarrhea) was less in the Col group than in the CH group (2.27% vs 28.41%, 95% CI 0.01~0.26). In addition, changes in blood uric acid, alanine aminotransferase, aspartate aminotransferase and creatinine in the CH group were significantly larger compared to those in the Col group (P<0.05).

Conclusions: The Chuanhu anti-gout mixture was non-inferior to colchicine for the treatment of acute gouty arthritis. The study suggested that the Chuanhu anti-gout mixture can be considered an alternative choice for the treatment of acute gouty arthritis because of its lower incidence of adverse events and its protection of kidney and renal function.

Keywords: Chuanhu; acute gouty arthritis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Trial profile.
See this image and copyright information in PMC

References

    1. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443–9. - PubMed
    1. Rho YH, Zhu Y, Choi HK. The Epidemiology of Uric Acid and Fructose. Semin Nephrol. 2011;31:410–9. - PMC - PubMed
    1. Richette P, Bardin T. Gout. Lancet. 2010;375:318–28. - PubMed
    1. Miao Z, Li C, Chen Y. et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859–64. - PubMed
    1. Annemans L, Spaepen E, Gaskin M. et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheu Dis. 2008;67:960–6. - PMC - PubMed

Publication types